Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q'
Year: 2021
Type: erratum
Abstract: The authors regret that Dr Arteaga’s disclosures were not complete in the original publication. Dr Arteaga’s full disclosure should read as follows: CLA: grant support: Pfizer, Lilly, Radius, PUMA Biotechnology, Bayer, Takeda, Symphogen; honoraria: advisory board/steering committee: Daiichi Sankyo, ABBVIE, Novartis, Lilly, Sanofi, Radius, Taiho Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, Dr Arteaga receives compensation for his role in the Scientific Advisory Board of the Komen Foundation, unrelated to this work; stock options: Provista, Y-TRAP. LNH: patents, royalties, other intellectual property—Philips Healthcare. The authors would like to apologise for any inconvenience caused. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QAnnals of OncologyVol. 30Issue 11PreviewThe National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic testing to direct refractory cancer patients to molecularly targeted treatment subprotocols. This treatment subprotocol was designed to screen for potential signals of efficacy of ado-trastuzumab emtansine (T-DM1) in HER2-amplified histologies other than breast and gastroesophageal tumors. Full-Text PDF Open Archive
Source: Annals of Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, OHSU Knight Cancer Institute, Thomas Jefferson University, National Cancer Institute, Center for Cancer Research, Dana-Farber Cancer Institute, National Institutes of Health, Frederick National Laboratory for Cancer Research, The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center, University of Pennsylvania, Massachusetts General Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W3172947477